Clinical trials
Prostate Cancer Metastatic Disease clinical trials
Below are recruiting prostate cancer metastatic disease clinical trials, each written for real people, not researchers. We’re tracking 605 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07090148RecruitingPhase 1
Vaccine plus immunotherapy for prostate cancer that has returned
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
Madison, WisconsinAges 18 years+ - NCT07089550Recruiting
PSMA PET scans to track treatment response in advanced prostate cancer
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Bologna, ItalyAges 18 years+ - NCT07080242RecruitingPhase 1
Study of BL-M14D1 for small cell lung cancer and neuroendocrine tumors
This trial tests an investigational drug, BL-M14D1, for people with certain types of neuroendocrine tumors or small cell lung cancer that have progressed after standard treatment. The drug targets a protein called DLL3 found on these cancer cells, which may help shrink tumors or slow their growth.
Huntsville, AlabamaAges 18 years+ - NCT07073794RecruitingPhase 2
Home versus clinic cancer therapy for Black men with prostate cancer
This study looks at whether giving certain prostate cancer treatments at home (instead of the clinic) works as well for Black men. If you qualify, you may get your regular treatment at home with a nurse.
Jacksonville, FloridaAges 18 years+ - NCT07059884Recruiting
Exercise program to help people with cancer stay active
This trial tests a distance-based exercise program designed to help people on chemotherapy maintain their physical function and prevent disability. It is for patients with certain cancers who are working full-time and can participate in moderate physical activity.
Dublin, CaliforniaAges 18 years+ - NCT07052578Recruiting
Aggressive prostate cancer study with HRR blood test
This study looks at men with aggressive, high-volume metastatic prostate cancer that is still sensitive to hormone therapy. It will analyze a blood test for HRR gene mutations (like BRCA) to help understand treatment patterns.
ArkhangelskAges 18 years+ - NCT07050394RecruitingEarly Phase 1
Experimental drug for advanced colorectal cancer
This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.
Shanghai, None SelectedAges 18 years+ - NCT07054346RecruitingPhase 1
Radioactive drugs before prostate surgery for high-risk prostate cancer
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
San Francisco, CaliforniaAges 18 years+ - NCT06992232RecruitingPhase 2
Radiation or surgery plus hormone therapy for prostate cancer that has spread
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
Nanjing, JiangsuAges 18–80 - NCT07038304RecruitingPhase 2
Radiation for cancer growth in prostate cancer that stopped responding to hormones
This trial tests whether giving precise radiation to a few spots of cancer growth can help control prostate cancer that has stopped responding to hormone therapy. It is for people with up to 3 growing or new spots of cancer on a special scan.
GroningenAges 18 years+ - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Huntsville, AlabamaAges 18 years+ - NCT07027124RecruitingPhase 2
High-risk prostate cancer treatment before and after surgery
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
New York, New YorkAges 18 years+ - NCT07015138Recruiting
Comparing two radiation approaches for prostate cancer that has spread a little
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
Beijing, Beijing MunicipalityAges 18–85 - NCT07005154RecruitingPhase 2
Study of ASP5541 for metastatic prostate cancer
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
Huntsville, AlabamaAges 18 years+ - NCT07004582Recruiting
Lab study using mini-tumors to test prostate cancer treatments
This trial uses leftover tumor tissue from biopsies or brachytherapy to grow mini-tumors in the lab. Researchers want to test different treatments on these mini-tumors to find the best options for patients with high-risk or recurrent prostate cancer.
Heerlen, LimburgAges 18 years+ - NCT07002320RecruitingPhase 1/Phase 2
Testing SX-682 plus apalutamide for advanced prostate cancer
This trial tests a new combination of two drugs (SX-682 and apalutamide) for men with metastatic prostate cancer that is no longer responding to standard hormone therapy. The goal is to see if adding SX-682 can help apalutamide work better.
BellinzonaAges 18 years+ - NCT05577689Recruiting
New treatment target study for metastatic prostate cancer
This trial studies a new therapy target for people with prostate cancer that has spread to other parts of the body. You may be a candidate if you can provide a cancer tissue sample and are able to consent to the study.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06978296Recruiting
HIMARS: Stereotactic radiation for prostate cancer spread
This trial tests adding targeted radiation (SRT) to bone or lymph node metastases in men with prostate cancer that has continued to grow despite hormone therapy, chemo, or other treatments. The goal is to see if radiation can help control the disease and improve outcomes.
Saint-HerblainAges 18 years+ - NCT06215508Recruiting
Smartwatch and geriatric assessment for older men with prostate cancer
This trial tests whether using a smartwatch along with a geriatric assessment can help doctors better manage the health of older men with metastatic prostate cancer who are about to start a new type of hormone therapy. It aims to improve quality of life and treatment outcomes.
Chicago, IllinoisAges 18 minutes+ - NCT06970119RecruitingPhase 1/Phase 2
Study of INR102 for advanced prostate cancer (Phase 1/2)
This trial tests a new investigational drug called INR102 for prostate cancer that has spread and stopped responding to standard treatments. It's given by injection, and the study will check if it's safe and if it can shrink or slow the cancer.
Wuxi, JiangsuAges 18 years+ - NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
Boston, MassachusettsAges 40 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Tucson, ArizonaAges 18 years+ - NCT06927635RecruitingPhase 2
SBRT vs standard care for prostate cancer that has spread to a few spots
This trial tests whether targeted radiation (SBRT) to a few sites of cancer spread can help men whose prostate cancer has stopped responding to hormone therapy but has not spread to many places. You may benefit if you have a limited number of growing spots outside the brain or spine.
Toronto, OntarioAges 18–100 - NCT06866938RecruitingPhase 2
Second course of PSMA-targeted radiation for prostate cancer
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
BordeauxAges 18 years+
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer metastatic disease?
- Yes. Clin2 currently lists 605 recruiting prostate cancer metastatic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer metastatic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer metastatic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.